Hartkopf A D, Banys M, Krawczyk N, Wallwiener M, Schneck H, Neubauer H, Fehm T
Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen.
Department of Obstetrics and Gynecology, Marienkrankenhaus Hamburg, Hamburg.
Geburtshilfe Frauenheilkd. 2011 Dec;71(12):1067-1072. doi: 10.1055/s-0031-1280463.
Disseminated tumor cells (DTC) are routinely detected in bone marrow (BM) in 30-40 % of primary breast cancer patients. Positive BM status at the time of diagnosis as well as DTC persistence after therapy are strong independent prognostic factors. Since repeated BM aspirations are not well tolerated, detection of single tumor cells in peripheral blood (circulating tumor cells; CTC) have become of interest in recent years. CTC are found in 10-80 % breast cancer patients. Variability can be explained by stage of the disease and detection method. Emerging data have shown CTC to be of prognostic relevance for both, patients with primary and metastatic disease. The assessment of CTC in blood may become an important biomarker for prognostication and therapy monitoring. Determination of their molecular characteristics will enable specific targeting of minimal residual as well as metastatic disease. This review summarizes recent research and future perspectives.
在30%-40%的原发性乳腺癌患者的骨髓（BM）中，常规可检测到播散性肿瘤细胞（DTC）。诊断时骨髓状态呈阳性以及治疗后DTC持续存在是强有力的独立预后因素。由于反复进行骨髓穿刺的耐受性不佳，近年来，对外周血中单个肿瘤细胞（循环肿瘤细胞；CTC）的检测备受关注。在10%-80%的乳腺癌患者中可发现CTC。这种变异性可由疾病分期和检测方法来解释。新出现的数据表明，CTC对原发性疾病和转移性疾病患者均具有预后相关性。血液中CTC的评估可能成为预后和治疗监测的重要生物标志物。确定其分子特征将能够对微小残留病以及转移性疾病进行特异性靶向治疗。本综述总结了近期的研究及未来展望。
